<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184417</url>
  </required_header>
  <id_info>
    <org_study_id>AlamedaCountyMC</org_study_id>
    <nct_id>NCT01184417</nct_id>
  </id_info>
  <brief_title>Phenobarbital for Acute Alcohol Withdrawal</brief_title>
  <official_title>Phenobarbital Versus Placebo for Acute Alcohol Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Rosenson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alameda County Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alameda County Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based
      alcohol withdrawal protocol will be associated with decreased need for ICU admission,
      continuous lorazepam infusion and will not be associated with increased adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Requiring Continuous Lorazepam Infusion</measure>
    <time_frame>1 year</time_frame>
    <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Requiring ICU Admission</measure>
    <time_frame>1 year</time_frame>
    <description>admission to intensive care unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Lorazepam Required Per Patient Per Admission</measure>
    <time_frame>1 year</time_frame>
    <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>1 year</time_frame>
    <description>hospital LOS, per patient, in hours from admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>mortality in study patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Phenobarbital group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg/kg IV phenobarbital in 100 ml saline</intervention_name>
    <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
    <arm_group_label>Phenobarbital group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 m l saline</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Need for admission to hospital for acute alcohol withdrawal

        Exclusion Criteria:

          -  allergy to phenobarbital, lorazepam, age&lt;18 or &gt;65
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alameda County Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <results_first_submitted>February 18, 2012</results_first_submitted>
  <results_first_submitted_qc>March 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2012</results_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alameda County Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Rosenson</investigator_full_name>
    <investigator_title>Jonathan Rosenson MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenobarbital Group</title>
          <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>100 ml saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenobarbital Group</title>
          <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>100 ml saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="12"/>
                    <measurement group_id="B2" value="48" spread="17"/>
                    <measurement group_id="B3" value="47" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Requiring Continuous Lorazepam Infusion</title>
        <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Continuous Lorazepam Infusion</title>
          <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Requiring ICU Admission</title>
        <description>admission to intensive care unit</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring ICU Admission</title>
          <description>admission to intensive care unit</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O2" value="25" lower_limit="4" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Lorazepam Required Per Patient Per Admission</title>
        <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lorazepam Required Per Patient Per Admission</title>
          <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="45" lower_limit="7" upper_limit="49"/>
                    <measurement group_id="O2" value="49" spread="37" lower_limit="7" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>hospital LOS, per patient, in hours from admission to discharge</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>hospital LOS, per patient, in hours from admission to discharge</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="54" upper_limit="114"/>
                    <measurement group_id="O2" value="118" lower_limit="47" upper_limit="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</title>
        <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</title>
          <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</title>
        <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</title>
          <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="-11" upper_limit="23"/>
                    <measurement group_id="O2" value="22" lower_limit="-11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</title>
        <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</title>
          <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</title>
        <description>mortality in study patients</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</title>
          <description>mortality in study patients</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phenobarbital Group</title>
          <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>100 ml saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Rosenson MD</name_or_title>
      <organization>Alameda County Medical Center</organization>
      <phone>510-407-6743</phone>
      <email>jonrosenson@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

